

FOI Ref: 26/168

16<sup>th</sup> April 2026

Eastbourne District General Hospital  
Kings Drive  
Eastbourne  
East Sussex  
BN21 2UD

Tel: 0300 131 4500  
Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

**Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

- |                                 |                   |
|---------------------------------|-------------------|
| • Atezolizumab (Tecentriq)      | 14                |
| • Durvalumab (Imfinzi)          | 2                 |
| • Nivolumab (Opdivo)            | 0                 |
| • Pembrolizumab (Keytruda)      | 36                |
| • Chemotherapy                  | 63                |
| • Radiotherapy                  | Please see below. |
| • Chemotherapy AND Radiotherapy | Please see below. |
| • Osimertinib                   | 30                |

Please note that East Sussex Healthcare NHS Trust does not provide a Radiotherapy Service. Patients requiring Radiotherapy or Chemotherapy and Radiotherapy are treated by University Hospitals Sussex NHS Foundation Trust.

Please refer this part of your required direct to them via the following:

Email [uhsussex.foi@nhs.net](mailto:uhsussex.foi@nhs.net)

**Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?**

0.

**Q3. How many patients has your Trust treated in total in the past 3 months for**

- |                                      |   |
|--------------------------------------|---|
| • Stage 2 Non-Small Cell Lung Cancer | 7 |
| • Stage 3 Non-Small Cell Lung Cancer | 5 |

**Q4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

- **Atezolizumab** 0
- **Pembrolizumab monotherapy** 2
- **Pembrolizumab monotherapy (subcutaneous injection formulation only)** 0
- **Pembrolizumab with chemotherapy** 4
- **Pembrolizumab with chemotherapy (subcutaneous injection formulation only)** 0
- **Nivolumab** 0
- **Osimertinib** 1
- **Durvalumab** 2
- **Chemotherapy** 7
- **Radiotherapy** Please refer to question 1.
- **Chemotherapy + Radiotherapy** Please refer to question 1.

**Q5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:**

- **Chemotherapy** 1
- **Radiotherapy** Not applicable, please refer to question 1.
- **Chemotherapy + Radiotherapy** Not applicable, please refer to question 1.

**Q6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

- **Durvalumab** 1

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at [esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net) quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team  
East Sussex Healthcare NHS Trust  
0300 131 4716  
Core Hours of Business: Monday to Friday 9.00am to 4.00pm